Open AccessA Biomicrofluidic Screening Platform for Dysfunctional Endothelium‐Targeted Nanoparticles and Therapeutics
Author(s) -
Bazban-Shotorbani Salime,
Gavins Felicity,
Kant Krishna,
Dufva Martin,
Kamaly Nazila
Publication year - 2022
Publication title -
advanced nanobiomed research
Language(s) - English
Resource type - Journals
ISSN - 2699-9307
DOI - 10.1002/anbr.202100092
Subject(s) - adherens junction , endothelium , microbiology and biotechnology , downregulation and upregulation , receptor , cancer research , ve cadherin , inflammation , cell adhesion molecule , endothelial stem cell , medicine , immunology , chemistry , cell , in vitro , biology , cadherin , biochemistry , gene
The internal surfaces of all blood and lymphatic vessels are lined with an endothelium, which tightly controls and regulates the permeability of biological molecules. A dysfunctional endothelium (Dys‐En) is a hallmark of many diseases, including atherosclerosis. Dys‐En in atherosclerosis leads to loss of adherens junctions between cells, thus enhancing permeability and upregulation of adhesion receptors such as vascular cell adhesion molecule 1 (VCAM‐1). Both this enhanced permeability of the endothelium and associated upregulated endothelial cell surface receptors can be exploited in nanomedicine targeting to atherosclerotic plaques. However, the relationship between targeting ligand and nanoparticle (NP) size is not well understood within this context. Herein, a biomicrofluidic model of Dys‐En is developed and this platform is used to screen VCAM‐1 targeted NPs. Screening of NPs with varying properties under flow shows that size plays a dominant role in NP targeting, with NPs in the range of 30–60 nm showing increased targeting to Dys‐En. Moreover, treatment of Dys‐En‐on‐a‐chip with Annexin A1, as a novel proresolving mediator of inflammation, results in restoration of adherens junctions and normalization of the barrier integrity. The results demonstrate utility of using “Dys‐En‐on‐a‐chip” as a screening platform for Dys‐En‐targeted nanomedicines and biologics.